Do GLP-1 drugs shield you from tempting food ads? new study investigates
NCT ID NCT07505134
First seen Apr 30, 2026 · Last updated Jun 20, 2026 · Updated 11 times
Summary
This study looks at whether GLP-1 weight-loss medications reduce cravings and unhealthy food choices triggered by food advertisements. Fifty adults taking tirzepatide will view food or tech ads and report their cravings and food intake. The goal is to understand if these drugs make people less vulnerable to external food cues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLP-1 are added.
By submitting, you agree to our Terms of use
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GLP-1 medication (tirzepatide)
What this could lead to
If successful, this could help explain how GLP-1 drugs reduce cravings and improve weight loss, potentially leading to better treatments for obesity.
What could go wrong
This is a small, early-stage observational study with only 50 participants. It measures responses to ads, not long-term weight loss, so results may not apply broadly.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.